MWNA
KIN

Marshall Wace North America’s Kindred Biosciences, Inc. KIN Stock Holding History

Marshall Wace North America’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,910
Closed -$59K – 1731
2019
Q4 		$59K Buy
+6,910
New +$53.9K ﹤0.01% 1136
2018
Q3 		– Sell
-84,825
Closed -$903K – 1534
2018
Q2 		$903K Buy
+84,825
New +$827K 0.01% 953

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Marshall Wace North America's KIN Position: Q1 2020 in Review

Marshall Wace North America sold out of Kindred Biosciences, Inc. (KIN) in Q1 2020, closing a stake of 6,910 shares — an estimated $59K sold.

Marshall Wace North America first reported a position in KIN in Q2 2018 and held it in 2 quarters. The position peaked at $903K in Q2 2018. 77 funds tracked by Wall St. Rank hold KIN as of Q1 2020.

  • Marshall Wace North America reported no remaining Kindred Biosciences, Inc. position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace North America sold 6,910 Kindred Biosciences, Inc. shares in Q1 2020, an estimated $59K.
  • Marshall Wace North America first reported a position in Kindred Biosciences, Inc. in Q2 2018 and held it in 2 quarters.
  • Marshall Wace North America's Kindred Biosciences, Inc. position peaked at $903K in Q2 2018.
  • 77 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.